Literature DB >> 25381479

Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology.

Mads Hald Andersen1.   

Abstract

The immune system is a complex arrangement of cells and molecules that preserve the integrity of the organism by eliminating all elements judged to be dangerous. Several regulatory mechanisms function to terminate immune responses to antigens, return the immune system to a basal state after the antigen has been cleared, and maintain unresponsiveness, or tolerance, to self-antigens. In recent years, reports have described T cell responses to several proteins involved in regulating the immune system, particularly under malignant conditions. The present review highlights specific T cells that recognize proteins involved in three, well-defined immunosuppressive mechanisms: (1) inhibitory T cell pathways (i.e., PD-L1), (2) regulatory T cells (i.e., Foxp3(+)), and (3) metabolic enzymes, like indoleamine-2,3-dioxygenase. Cytotoxic T cells can eliminate regulatory cells, thereby suppressing and/or delaying local immune suppression; conversely, regulatory CD4(+) and non-cytotoxic CD8(+) T cells enhance target-mediated immune suppression. The apparent lack of tolerance against endogenous proteins expressed by regulatory cells is intriguing, because it suggests that self-reactive T cells play a general role of fine-tuning the immune system. Thus, T cell responses may be generally used to maintain the homeostasis of the immune system. Further exploration is warranted to investigate the potential role of auto-reactive T cells under different physiological and/or pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25381479     DOI: 10.1007/s12026-014-8559-3

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  76 in total

Review 1.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

2.  Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.

Authors:  S Munir; G H Andersen; A Woetmann; N Ødum; J C Becker; M H Andersen
Journal:  Leukemia       Date:  2013-04-18       Impact factor: 11.528

Review 3.  Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Authors:  Alexander J Muller; George C Prendergast
Journal:  Curr Cancer Drug Targets       Date:  2007-02       Impact factor: 3.428

4.  Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.

Authors:  Rikke Bæk Sørensen; Tania Køllgaard; Rikke Sick Andersen; Joost Huibert van den Berg; Inge Marie Svane; Per thor Straten; Mads Hald Andersen
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

5.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

6.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

7.  Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice.

Authors:  Christophe M Filippi; Elizabeth A Estes; Janine E Oldham; Matthias G von Herrath
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

8.  The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Authors:  Rikke Baek Sørensen; Linda Berge-Hansen; Niels Junker; Christina Aaen Hansen; Sine Reker Hadrup; Ton N M Schumacher; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

9.  CD4 responses against IDO.

Authors:  Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  2 in total

1.  Introduction to the special issue on the 9th International Congress on Autoimmunity.

Authors:  Eric Rosenthal; Mathilde Versini; Pierre-Yves Jeandel; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Authors:  Troels Holz Borch; Lotte Engell-Noerregaard; Trine Zeeberg Iversen; Eva Ellebaek; Özcan Met; Morten Hansen; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2016-07-08       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.